Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karen Lewandowski

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Dermatology Reports|November 12, 2014
Resolution of Cullen's sign in patient with metastatic melanoma responding to hypoxia-activated prodrug TH-302Glen J Weiss, Karen Lewandowski, Jon Oneall, et al.
The American Surgeon|June 11, 2021
Shift Length and Shift Length Preference Among Acute Care SurgeonsJohn Kepros, Susan Haag, Karen Lewandowski, et al.
Investigational New Drugs|April 12, 2012
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancerGlen J Weiss, Ross C Donehower, Tara Iyengar, et al.
Cancer Chemotherapy and Pharmacology|January 1, 2013
A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignanciesJohn F Deeken, Rebecca Slack, Glen J Weiss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2011
Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignanciesGlen J Weiss, Jeffrey R Infante, E Gabriela Chiorean, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Dermatology Reports|November 12, 2014
Resolution of Cullen's sign in patient with metastatic melanoma responding to hypoxia-activated prodrug TH-302Glen J Weiss, Karen Lewandowski, Jon Oneall, et al.
The American Surgeon|June 11, 2021
Shift Length and Shift Length Preference Among Acute Care SurgeonsJohn Kepros, Susan Haag, Karen Lewandowski, et al.
Investigational New Drugs|April 12, 2012
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancerGlen J Weiss, Ross C Donehower, Tara Iyengar, et al.
Cancer Chemotherapy and Pharmacology|January 1, 2013
A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignanciesJohn F Deeken, Rebecca Slack, Glen J Weiss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2011
Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignanciesGlen J Weiss, Jeffrey R Infante, E Gabriela Chiorean, et al.
Pageof 1